Month: April 2022

Nokia CorporationStock Exchange Release8 April 2022 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 08.04.2022 Espoo, Finland – On 8 April 2022 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 246,389 5.01CEUX 11,988 5.01AQEU 10,707 5.02TQEX 1,416 5.02Total 270,500 5.01* Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the current authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in traches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation...

ROANOKE, Va., April 08, 2022 (GLOBE NEWSWIRE) — Robert Johnston was appointed to the Board of Directors of RGC Resources, Inc. (NASDAQ: RGCO) at a board meeting held on April 7, 2022. He will serve as a Class B Director. “We are very pleased to have Rob join our Board. His extensive public company and utility experiences will be valuable to our shareholders, Board and company”, said Paul Nester, President and CEO of RGC Resources. Mr. Johnston serves as the Chief Strategy Officer for The InterTech Group, Inc. (TIG). In this capacity, he is responsible for merger and acquisition activities, investments and communications as well as oversight of a number of TIG operating companies. Mr. Johnston previously served as the President and Chief Executive Officer as well as Vice Chairman of Hudson Bay Company. RGC Resources, Inc. provides...

CHINO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Chino Commercial Bank, the wholly owned subsidiary of Chino Commercial Bancorp (OTC: “CCBC”), was recently recognized by The Findley Reports on Financial Institutions by receiving Findley’s highest rating of “Super Premier Performing Bank.” The Bank, which has branches in Chino, Ontario, Rancho Cucamonga, and Upland, received the recognition from Findley for its financial and operational performance during the 2021 year. The recognition by Findley was based upon multiple factors, including Profitability, Return on beginning Equity and Loan performance. Dann H. Bowman, President and CEO, stated, “We are very pleased to receive Findley Reports’ highest rating of Super Premier Performing. The local and regional economies continue to improve and we are pleased to be a part of this growing...

SANTA ROSA, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Luther Burbank Corporation (the “Company”) (NASDAQ: LBC), the holding company for Luther Burbank Savings (the “Bank”), announced today that it will release its financial results as of and for the quarter ended March 31, 2022 after the market closes on Tuesday, April 26, 2022. Simone Lagomarsino, President and Chief Executive Officer of Luther Burbank Corporation, and Laura Tarantino, Executive Vice President and Chief Financial Officer, will host a conference call on Wednesday, April 27, 2022 at 8:00 AM (PT) to discuss the Company’s results for the period. Analysts, investors, and the general public may listen to a discussion of the Company’s quarterly performance and a question/answer session by using the phone number or live webcast link listed below. The webcast will include...

– Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy – – Rate of eligible MAGE-A4 expression was 67% for synovial sarcoma, and ranged from 20%-35% for squamous cell lung, bladder, esophagogastric junction, ovarian, head and neck, and esophageal cancers- PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 08, 2022 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the multinational, multicenter, screening protocol (NCT02636855) at the American Association for Cancer Research (AACR) annual meeting in a poster entitled “Identifying MAGE-A4-Positive Tumors for SPEAR T-Cell Therapies in HLA-A*02–Eligible Patients”. “This large clinical dataset continues building the...

First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate superior performance to the only clinical-stage competitor Monotherapy activity and broad combination potential Investigational New Drug (IND) application cleared; clinical trial to commenceLEXINGTON, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced the first presentation of preclinical data from AGEN1571 – a novel anti-ILT2 antibody designed to modulate tumor-associated macrophages, T, NK and NKT cells. These data are being presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-12 in New Orleans, LA. “The...

Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibodyIn preclinical studies and in blood samples from patients with advanced cancers, treatment with EOS-448 results in a reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functionsWATERTOWN, Mass. and GOSSELIES, Belgium, April 08, 2022 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of potentially differentiated immuno-oncology therapeutics for patients, today announced a presentation featuring preclinical and clinical analyses supporting...

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022. “The data we presented at this year’s AACR meeting highlight the breadth and diversity of our scientific efforts, as we continue to expand our ability to deliver off-the-shelf cell therapies with the potential to disrupt the cancer treatment landscape,” said James Trager, PhD, Chief Scientific Officer of Nkarta. “Our research activities are designed to extend the capabilities of NK cells, to lay the groundwork for further pipeline...

The recommended phase 2 dose was determined at 480 mg AFM24 has demonstrated a well-managed safety profile Pharmacodynamic activity was observed at doses of 160 mg and higher The maximum tolerated dose was not reached and the dose escalation continues at 720 mg For the broad clinical AFM24 program, patients are recruited in three studies, two of which are combination studies, in 7 indicationsHEIDELBERG, Germany, April 08, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data from the dose escalation phase of the phase 1/2a study with the Company’s Innate Cell Engager (ICE®) AFM24 as monotherapy at the Annual Meeting of the American Association of Cancer Research (AACR)....